ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1805

Longitudinal Analysis of IFN Status and Disease Characteristics in SLE

Melissa Northcott1, Alberta Hoi2, Rachel Koelmeyer3 and Eric Morand4, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Monash University, Clayton, Victoria, Australia, 4Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

Meeting: ACR Convergence 2020

Keywords: interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The type 1 interferon (IFN) cytokine family is key to the pathogenesis of SLE, evidenced by the expression of IFN stimulated genes (ISGs) in most patients. Phenotypic differences between SLE patients who express ISGs (IFN high) and those who do not (IFN low) are not well understood. With the emergence of IFN blocking drugs, it is important to examine the clinical utility of IFN status testing.  We report the results of longitudinal analysis of IFN and clinical status in SLE.

Methods: 205 patients meeting ACR criteria for SLE were recruited at a tertiary centre where extensive clinical data are collected prospectively on consenting subjects. Whole blood RNA samples were collected in PAXgene tubes. IFN status was determined using the IFN module from Modular Immune Profile Test (DxTerity Diagnostics).

Results: 729 results (205 patients, 142 with longitudinal samples) were analysed. At baseline, 62.9% of patients were IFN high, 30.2% IFN low and 6.8% borderline. Compared to IFN low patients, IFN high were more likely to be of Eastern Asian ethnicity (45.0 vs 25.8%, p = 0.01), were younger at SLE onset (median [IQR] 27[18-35] vs 33 [25-47] years, p = 0.0001), and were more likely to be positive for anti-Ro (65.3 vs 34.7% p = < 0.0001), anti-La (29.2 vs 11.3% p = 0.01) and anti-RNP (36.1% vs 15.1% p = 0.007) antibodies. In patients with multiple samples, 87.3% had stable ISG status. In longitudinal follow up (median 630 [459-707] days), IFN high patients had higher disease activity (median [IQR] time adjusted mean SLEDAI2K (4.2 [2.8-5.7] vs 2.0 [1.3-4.2], p=< 0.0001), more flares (mild/moderate 53.5 vs 25.8%, p = 0.0003; severe 26.4 vs 6.5%, p = 0.0009) and spent less observed time in lupus low disease activity state (LLDAS) (median 55.5% [26.3-85.5] vs 84.0 [53.0-100]%, p = 0.0003). IFN high patients were more likely to have active arthritis (21.7 vs 6.5%, p = 0.007), skin disease (38.8 vs 14.5%, p = 0.007), leukopenia (26.4 vs 6.5%, p = 0.0009) and haematuria (20.2 vs 8.1%, p = 0.03). More IFN high patients required DMARD therapy (74.6 vs 55.9%, p = 0.02) and IFN high patients had higher prednisolone exposure (median time-adjusted mean dose 1.7 [0-5.7] vs 0.0[0-2.9] mg, p = 0.004). There was no difference in overall SLICC damage index, however there were differences in damage domains. IFN low patients had more malignancy (11.6 vs 2.4%, p = 0.01) and diabetes (13.3 vs 1.6%, p = 0.002). IFN high patients trended towards more mucocutaneous damage (19.2 vs 8.3%, p=0.08). However, in individual patients, there was no association between ISG level and any disease activity marker over time. 
Of 18 patients with varying IFN status over time, 12 had ISG fluctuations that were < 2SD from the mean fluctuation seen in stable ISG patients.  Of the remaining 6 patients with larger ISG fluctuations, 5 had high dose ( ≥25mg) prednisolone or cyclophosphamide therapy temporally associated with ISG reduction.

Conclusion: IFN high SLE patients had significantly more disease activity than IFN low patients. They were more likely to be of Asian than Caucasian ethnicity, had younger onset of disease and displayed more auto-antibodies. The majority of patients had stable IFN status, and major changes in ISG expression related to high dose immunosuppression.


Disclosure: M. Northcott, None; A. Hoi, None; R. Koelmeyer, None; E. Morand, AstraZeneca, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Janssen, 2, 5, Merck Serono, 2, 5, Neovacs, 5, Sandoz, 5, Novartis, 8, AbbVie, 5, Amgen, 5, Biogen, 5.

To cite this abstract in AMA style:

Northcott M, Hoi A, Koelmeyer R, Morand E. Longitudinal Analysis of IFN Status and Disease Characteristics in SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/longitudinal-analysis-of-ifn-status-and-disease-characteristics-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-analysis-of-ifn-status-and-disease-characteristics-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology